October 25, 2021 7:52am
Sector earnings begin this today as uniQure MV (QURE) releases
Pre-open indications: 1 SELLs into Strength, 4 BUYs and with 1 Pump (or No Promote)
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.02% (+6 points), S&P futures are UP +0.10% (+4.50 point) and NASDAQ futures are UP +0.23% (+56 point)
U.S. stock futures were up slightly in Monday’s pre-market,
European stocks were mixed
Asia-Pacific stocks were also mixed
Henry’omics:
The stock market rally had solid gains last week.
The Dow rose 1.1%, the S&P 500 index climbed 1.65% while the Nasdaq gained 1.3% with the small-cap Russell 2000 advanced nearly 1% in last week's stock market trading
Global investors also continue to track inflation, which has risen sharply around the world as spiking energy prices and supply chain bottlenecks converge, sending euro zone inflation to a 13-year high in September. <CNBC>
If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Friday’s evening’s recap: “RegMed Investors’ (RMi) closing bell: a rout that’s been coming. My skepticism has played through” … https://www.regmedinvestors.com/articles/12151
Q4: October, 7 positive and 9 negative closes
Q3/21:
- September, 1 holiday, 10 positive and 10 negative close
- August - 12 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
SELL with a Pump or no promote:
Biostage (BSTG) closed down again -$0.156 with 516 shares traded after Thursday’s -$0.095 with 265 shares traded after Wednesday’s +$0.30 with 8,356 shares traded after being flat at $3.00 with 1,488 shares traded after Monday’s -$0.065 with 4,041 shares traded, For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
- What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
SELL into Strength:
bluebird bio (BLUE) closed up +$0.41 to $20.80 with a negative -$0.30 or -1.44% pre-open indication.
BUY:
Global Blood Therapeutics (GBT) closed up +$0.21 to $31.57 after Thursday’s +$1.64 to $31.36, Wednesday’s $29.79, Tuesday’s $30.31 and last Monday’s $30.71 with a negative -$0.40 or +1.27% pre-open indication,
Ultragenyx (RARE) closed down -$0.18 to $78.22 after Thursday’s +$1.44 and Wednesday’s -$1.08 and has a positive +$1.77 or +2.26% pre-open indication.
Voyager Therapeutics (VYGR) closed down -$0.12 to $3.79 with a positive +$0.19 or +5.01% after market indication
Sage Therapeutics (SAGE) closed up +$0.19 to $41.42 after Thursday’s +$0.33 to $41.23, Wednesday’s +$0.61 to $40.90 with a positive +$0.18 or +0.43% aftermarket indication,
The BOTTOM LINE: Don't let earnings week take advantage of you.
Be ready to act on up-coming earnings news, good or bad, but don't be too hasty.
It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.
As I stated, it … was time to profit … before declines!
The stem, cell and gene therapy earnings will be beginning 10/28 Thursday with Alnylam Pharmaceuticals leading the releases with Sage Therapeutics (SAGE) on 11/2, Vericel (VCEL) on 11/9 and Athersys ATHX) coming 11/15 (to date).
What changes, there is too much uncertainty, that doesn’t appeal to my continued skepticism …
Sector stocks have traded choppily over the past several weeks as investors contemplated the implications of upcoming earnings releases that are coming …
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
